Leo Pharma strongly criticizes Danish Medicines Council

A letter from Leo Pharma to the agency reveals that the pharmaceutical company is not satisfied with the Danish Medicines Council's assessment of eczema treatment Adtralza.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
By andreas lønstrup, translated by catherine brett

Once again, the Danish Medicines Council has come under fire. According to Leo Pharma, the council has used the wrong methods to evaluate its eczema treatment Adtralza, affecting several assessment criteria.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading